within Pharmacolibrary.Drugs.ATC.D;

model D06AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.77,
    Cl             = 1.9666666666666662e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.012333333333333333,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D06AA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tetracycline is a broad-spectrum antibiotic used for the treatment of various bacterial infections including acne, respiratory tract infections, urinary tract infections, and some sexually transmitted infections. It was widely used in the past and is still approved for use today, though its use has declined due to resistance and newer antibiotics.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Mergenhagen, KA, et al., &amp; Russo, TA (2020). Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. <i>Antimicrobial agents and chemotherapy</i> 64(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02167-19\">10.1128/AAC.02167-19</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31871085/\">https://pubmed.ncbi.nlm.nih.gov/31871085</a></p></li><li><p>Tao, RE, et al., &amp; Feldman, SR (2023). Oral Tetracycline-Class Drugs in Dermatology: Impact of Food Intake on Absorption and Efficacy. <i>Antibiotics (Basel, Switzerland)</i> 12(7) –. DOI:<a href=\"https://doi.org/10.3390/antibiotics12071152\">10.3390/antibiotics12071152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37508248/\">https://pubmed.ncbi.nlm.nih.gov/37508248</a></p></li><li><p>Rodvold, KA, &amp; Pai, MP (2019). Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 69(Suppl 1) S16–S22. DOI:<a href=\"https://doi.org/10.1093/cid/ciz309\">10.1093/cid/ciz309</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31367744/\">https://pubmed.ncbi.nlm.nih.gov/31367744</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D06AA04;
